{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T16:29:45Z","timestamp":1790785785945,"version":"4.1.0"},"reference-count":70,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2022,11,4]],"date-time":"2022-11-04T00:00:00Z","timestamp":1667520000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Merck KGaA"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Even though growth hormone (GH) treatment is still the only active treatment option to correct growth failure and increase stature for patients with GH deficiencies, evidence has shown that non-adherence remains high. The aim of this review was to identify and review the existing interventional strategies that have been designed to address and improve adherence to GH treatment for pediatric patients and their families. An extensive search of several electronic databases was undertaken to identify relevant interventional studies, published in English, between 1985 and 2021. Additional search strategies included hand-searching topic review articles to identify eligible studies. Articles were screened against the inclusion eligibility criteria and data on sample characteristics, intervention features, and key findings was extracted. A total of fifteen interventional studies were included in the review. The interventions identified were divided into two broad categories: novel injection devices, and patient choice of device. In conclusions, this review acknowledges that there is a lack of evidence-based, theory-driven intervention strategies, designed with the purpose of optimizing treatment adherence and improve clinical and psychosocial outcomes.<\/jats:p>","DOI":"10.3390\/pharmaceutics14112373","type":"journal-article","created":{"date-parts":[[2022,11,4]],"date-time":"2022-11-04T04:00:51Z","timestamp":1667534451000},"page":"2373","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Interventions Designed to Improve Adherence to Growth Hormone Treatment for Pediatric Patients and Their Families: A Narrative Review"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6968-2749","authenticated-orcid":false,"given":"Selina","family":"Graham","sequence":"first","affiliation":[{"name":"School of Cancer and Pharmaceutical Sciences, King\u2019s College London, London SE1 9NQ, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia","family":"Quirke-McFarlane","sequence":"additional","affiliation":[{"name":"School of Cancer and Pharmaceutical Sciences, King\u2019s College London, London SE1 9NQ, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivian","family":"Auyeung","sequence":"additional","affiliation":[{"name":"School of Cancer and Pharmaceutical Sciences, King\u2019s College London, London SE1 9NQ, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6786-0166","authenticated-orcid":false,"given":"John","family":"Weinman","sequence":"additional","affiliation":[{"name":"School of Cancer and Pharmaceutical Sciences, King\u2019s College London, London SE1 9NQ, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,11,4]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.12968\/bjon.2012.21.18.1091","article-title":"Initiating growth hormone therapy for children and adolescents","volume":"21","author":"Acerini","year":"2012","journal-title":"Br. J. Nurs."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1159\/000350251","article-title":"Understanding the growth hormone therapy adherence paradigm: A systematic review","volume":"79","author":"Fisher","year":"2013","journal-title":"Horm. Res. Paediatr."},{"key":"ref_3","unstructured":"National Institute for Health and Clinical Excellence (NICE) (2022, September 25). Human Growth Hormone (Somatropin) for the Treatment of Growth Failure in Children. Available online: https:\/\/www.nice.org.uk\/guidance\/ta188."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"69","DOI":"10.6065\/apem.2040064.032","article-title":"Deciphering short stature in children","volume":"25","author":"Polidori","year":"2020","journal-title":"Ann. Pediatr. Endocrinol. Metab."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"688","DOI":"10.3389\/fendo.2018.00688","article-title":"Shared decision-making in growth hormone therapy: Implications for patient care","volume":"9","author":"Acerini","year":"2018","journal-title":"Front. Endocrinol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"S162","DOI":"10.4103\/2230-8210.84852","article-title":"History of growth hormone therapy","volume":"15","author":"Ayyar","year":"2011","journal-title":"Indian J. Endocrinol. Metab."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1136\/adc.2010.186205","article-title":"Indications for growth hormone therapy in children","volume":"97","author":"Kirk","year":"2012","journal-title":"Arch. Dis. Child."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.beem.2016.11.005","article-title":"Treatment of growth hormone deficiency in children, adolescents and at the transitional age","volume":"30","author":"Richmond","year":"2016","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.clinthera.2008.02.017","article-title":"Observations of nonadherence to recombinant human growth hormone therapy in clinical practice","volume":"30","author":"Haverkamp","year":"2008","journal-title":"Clin. Ther."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1159\/000493211","article-title":"Identifying potentially modifiable factors associated with treatment non-adherence in paediatric growth hormone deficiency: A systematic review","volume":"90","author":"Graham","year":"2018","journal-title":"Horm. Res. Paediatr."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"448","DOI":"10.3111\/13696998.2011.590829","article-title":"A review of biopsychosocial strategies to prevent and overcome early-recognized poor adherence in growth hormone therapy of children","volume":"14","author":"Haverkamp","year":"2011","journal-title":"J. Med. Econ."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"65S","DOI":"10.1378\/chest.130.1_suppl.65S","article-title":"Compliance, adherence, and concordance: Implications for asthma treatment","volume":"130","author":"Horne","year":"2006","journal-title":"Chest"},{"key":"ref_13","unstructured":"National Institute for Health and Clinical Excellence (NICE) (2022, September 25). Medicines Adherence: Involving Patients in Decisions about Prescribed Medicines and Supporting Adherence. Available online: https:\/\/www.nice.org.uk\/guidance\/cg76."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1111\/j.1365-2125.2012.04167.x","article-title":"A new taxonomy for describing and defining adherence to medications","volume":"73","author":"Vrijens","year":"2012","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"30","DOI":"10.7326\/M18-0543","article-title":"ESPACOMP Medication Adherence Reporting Guideline (EMERGE)","volume":"169","author":"Zullig","year":"2018","journal-title":"Ann. Intern. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1097\/00005650-200209000-00009","article-title":"Patient adherence and medical treatment outcomes: A meta-analysis","volume":"40","author":"DiMatteo","year":"2002","journal-title":"Med. Care"},{"key":"ref_17","unstructured":"Khan, R., and Socha-Dietrich, K. (2018). Investing in Medication Adherence Improves Health Outcomes and Health System Efficiency: Adherence to Medicines for Diabetes, Hypertension, and Hyperlipidaemia, OECD Publishing. OECD Health Working Papers; No. 105."},{"key":"ref_18","unstructured":"National Institute for Health and Clinical Excellence (NICE) (2022, September 25). Medicines Optimisation: The Safe and Effective Use of Medicines to Enable the Best Possible Outcomes. Available online: https:\/\/www.nice.org.uk\/guidance\/ng5."},{"key":"ref_19","unstructured":"World Health Organization (WHO) (2022, September 25). Adherence to Long-Term Therapies: Evidence for Action, Available online: https:\/\/www.who.int\/chp\/knowledge\/publications\/adherence_full_report.pdf."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3389\/fphar.2013.00091","article-title":"Determinants of patient adherence: A review of systematic reviews","volume":"4","author":"Kardas","year":"2013","journal-title":"Front. Pharmacol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/2049-3258-72-37","article-title":"Adherence influencing factors: A systematic review of systematic reviews","volume":"72","author":"Mathes","year":"2014","journal-title":"Arch. Public Health"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"46","DOI":"10.4158\/EP13194.OR","article-title":"Adherence to growth hormone therapy: Results of a multicenter study","volume":"20","author":"Aydin","year":"2014","journal-title":"Endocr. Pract."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Cutfield, W.S., Derraik, J.G., Gunn, A.J., Reid, K., Delany, T., Robinson, E., and Hofman, P.L. (2011). Non-compliance with growth hormone treatment in children is common and impairs linear growth. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0016223"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000351800","article-title":"Growth hormone treatment adherence in prepubertal and pubertal children with different growth disorders","volume":"80","author":"Hartmann","year":"2013","journal-title":"Horm. Res. Paediatr."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1136\/adc.2006.114249","article-title":"Monitoring of concordance in growth hormone therapy","volume":"93","author":"Kapoor","year":"2008","journal-title":"Arch. Dis. Child."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1159\/000437305","article-title":"Low treatment adherence in pubertal children treated with thyroxin or growth hormone","volume":"84","author":"Lass","year":"2015","journal-title":"Horm. Res. Paediatr."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"143","DOI":"10.4158\/EP.14.2.143","article-title":"Compliance and persistence in pediatric and adult patients receiving growth hormone therapy","volume":"14","author":"Rosenfeld","year":"2008","journal-title":"Endocr. Pract."},{"key":"ref_28","first-page":"314","article-title":"Adherence to somatotropin treatment administered with an electronic device","volume":"65","year":"2018","journal-title":"Endocrinol. Diabetes Nutr."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1007\/s40618-020-01218-4","article-title":"Adherence to treatment in children with growth hormone deficiency, small for gestational age and Turner syndrome in Mexico: Results of the Easypod Connect Observational Study (ECOS)","volume":"43","author":"Koledova","year":"2020","journal-title":"J. Endocrinol. Investig."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Bozzola, M., Colle, M., Halldin-Stenlid, M., Larroque, S., Zignani, M., and EasypodTM Survey Study Group (2011). Treatment adherence with the easypod growth hormone electronic auto-injector and patient acceptance: Survey results from 824 children and their parents. BMC Endocr. Disord., 11.","DOI":"10.1186\/1472-6823-11-4"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1007\/s40618-019-01046-1","article-title":"Adherence to growth hormone (GH) therapy in naive to treatment GH-deficient children: Data of the Italian cohort from the Easypod Connect Observational Study (ECOS)","volume":"42","author":"Centonze","year":"2019","journal-title":"J. Endocrinol. Investig."},{"key":"ref_32","first-page":"327","article-title":"Patient outcomes in the GHMonitor: The effect of delivery device on compliance and growth","volume":"2","author":"Desrosiers","year":"2005","journal-title":"Pediatr. Endocrinol. Rev."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1515\/jpem-2017-0146","article-title":"Initial patient choice of a growth hormone device improves child and adolescent adherence to and therapeutic effects of growth hormone replacement therapy","volume":"30","author":"Gau","year":"2017","journal-title":"J. Pediatr. Endocrinol. Metab."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1007\/s40618-016-0510-0","article-title":"Adherence in children with growth hormone deficiency treated with r-hGH and the easypod device","volume":"39","author":"Loche","year":"2016","journal-title":"J. Endocrinol. Investig."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/s13052-018-0548-z","article-title":"Improvement of treatment adherence with growth hormone by easypod device: Experience of an Italian centre","volume":"44","author":"Maggio","year":"2018","journal-title":"Ital. J. Pediatr."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1515\/jpem-2018-0067","article-title":"Improved adherence and growth outcomes with jet-delivered growth hormone","volume":"32","author":"Michaelidou","year":"2019","journal-title":"J. Pediatr. Endocrinol. Metab."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1530\/EC-19-0325","article-title":"Adherence and long-term outcomes of growth hormone therapy with easypod\u2122 in pediatric subjects: Spanish ECOS study","volume":"8","year":"2019","journal-title":"Endocr. Connect."},{"key":"ref_38","first-page":"1255","article-title":"Maintaining persistence and adherence with subcutaneous growth-hormone therapy in children: Comparing jet-delivery and needle-based devices","volume":"8","author":"Spoudeas","year":"2014","journal-title":"Patient Prefer. Adherence"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"455","DOI":"10.2147\/PPA.S43460","article-title":"User assessment of Norditropin NordiFlex\u00ae, a new prefilled growth hormone pen: A Phase IV multicenter prospective study","volume":"7","author":"Tauber","year":"2013","journal-title":"Patient Prefer. Adherence"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Van Dommelen, P., Koledova, E., and Wit, J.M. (2018). Effect of adherence to growth hormone treatment on 0\u20132 year catch-up growth in children with growth hormone deficiency. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0206009"},{"key":"ref_41","first-page":"18","article-title":"Factors determining patient choice of device for GH therapy","volume":"65","author":"Wickramasuriya","year":"2006","journal-title":"Horm. Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1159\/000357975","article-title":"Adherence to growth hormone therapy: A practical approach","volume":"81","author":"Bozzola","year":"2014","journal-title":"Horm. Res. Paediatr."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"g1687","DOI":"10.1136\/bmj.g1687","article-title":"Better reporting of interventions: Template for intervention description and replication (TIDieR) checklist and guide","volume":"348","author":"Hoffmann","year":"2014","journal-title":"BMJ"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Brearley, C., Priestley, A., Leighton-Scott, J., and Christen, M. (2007). Pharmacokinetics of recombinant human growth hormone administered by cool.click 2, a new needle-free device, compared with subcutaneous administration using a conventional syringe and needle. BMC Clin. Pharmacol., 7.","DOI":"10.1186\/1472-6904-7-10"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1177\/2042018817730545","article-title":"Patients\u2019 perceptions on the usability of the SurePal self-injection device for Omnitrope\u00ae: A questionnaire-based observational study conducted in paediatric patients in France","volume":"8","author":"Coutant","year":"2017","journal-title":"Ther. Adv. Endocrinol. Metab."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1185\/030079907X210589","article-title":"Patient acceptance of a novel electronic auto-injector device to administer recombinant human growth hormone: Results from an open-label, user survey of everyday use","volume":"23","author":"Dahlgren","year":"2007","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2906","DOI":"10.1016\/j.clinthera.2009.12.014","article-title":"Ease of use and acceptability of a new pen device for the administration of growth hormone therapy in pediatric patients: An open-label, uncontrolled usability test","volume":"31","author":"Fuchs","year":"2009","journal-title":"Clin. Ther."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1016\/j.clinthera.2010.11.007","article-title":"Ease of use and preference for a new disposable self-injection pen compared with a reusable pen for administering recombinant human growth hormone: A multicenter, 2-month, single-arm, open-label clinical trial in patient-caregiver dyads","volume":"32","author":"Pleil","year":"2010","journal-title":"Clin. Ther."},{"key":"ref_49","first-page":"803948","article-title":"Patient acceptance, ease of use, and preference for Norditropin NordiFlex with NordiFlex PenMate: Results from an open-label, user survey of everyday use","volume":"2011","author":"Keller","year":"2011","journal-title":"ISRN Endocrinol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1515\/jpem-2011-0395","article-title":"Children and adolescent acceptability of a new device system to administer human growth hormone: A pilot study","volume":"25","author":"Kappelgaard","year":"2012","journal-title":"J. Pediatr. Endocrinol. Metab."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1515\/jpem.2011.252","article-title":"Patient preference for a new growth hormone injection device: Results of an open-label study in Japanese pediatric patients","volume":"24","author":"Kappelgaard","year":"2011","journal-title":"J. Pediatr. Endocrinol. Metab."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1210\/jc.2013-2502","article-title":"24-month use of once-weekly GH, LB03002, in prepubertal children with GH deficiency","volume":"99","author":"Khadilkar","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1530\/EJE-16-0905","article-title":"Long-acting PEGylated recombinant human growth hormone (Jintrolong) for children with growth hormone deficiency: Phase II and phase III multicenter, randomized studies","volume":"177","author":"Luo","year":"2017","journal-title":"Eur. J. Endocrinol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1210\/jc.2015-3279","article-title":"A randomized safety and efficacy study of somavaratan (VRS-317), a long-acting rhGH, in pediatric growth hormone deficiency","volume":"101","author":"Moore","year":"2016","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_55","first-page":"389","article-title":"Acceptability of the reusable SurePal self-injection device for Omnitrope\u00ae among pediatric patients: Results from a questionnaire-based, cross-sectional, multicenter observational study","volume":"8","author":"Partsch","year":"2015","journal-title":"Med. Devices"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1016\/j.clinthera.2010.10.010","article-title":"Intuitiveness, ease of use, and preference of a prefilled growth hormone injection pen: A noninterventional, randomized, open-label, crossover, comparative usability study of three delivery devices in growth hormone-treated pediatric patients","volume":"32","author":"Pfutzner","year":"2010","journal-title":"Clin. Ther."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"61","DOI":"10.2147\/MDER.S59821","article-title":"Results from an international multicenter trial evaluating the ease-of-use of and preference for a newly developed disposable injection pen for the treatment of growth hormone deficiency in treatment-naive children and adults","volume":"7","author":"Pleil","year":"2014","journal-title":"Med. Devices"},{"key":"ref_58","first-page":"141","article-title":"Validation and ease of use of a new pen device for self-administration of recombinant human growth hormone: Results from a two-center usability study","volume":"6","author":"Rapaport","year":"2013","journal-title":"Med. Devices"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2147\/PPA.S149412","article-title":"A new pen device for injection of recombinant human growth hormone: A convenience, functionality and usability evaluation study","volume":"12","author":"Sauer","year":"2018","journal-title":"Patient Prefer. Adherence"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/j.1651-2227.1995.tb13867.x","article-title":"Patient evaluation of a new injection pen for growth hormone treatment in children and adults","volume":"411","author":"Sjoblom","year":"1995","journal-title":"Acta Paediatr. Suppl."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1530\/EJE-11-0536","article-title":"Long-acting pegylated human GH in children with GH deficiency: A single-dose, dose-escalation trial investigating safety, tolerability, pharmacokinetics and pharmacodynamics","volume":"165","author":"Rasmussen","year":"2011","journal-title":"Eur. J. Endocrinol."},{"key":"ref_62","first-page":"162","article-title":"Long-acting growth hormone preparations in the treatment of children","volume":"16","author":"Lal","year":"2018","journal-title":"Pediatr. Endocrinol. Rev."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"e2121","DOI":"10.1210\/clinem\/dgz149","article-title":"Long-acting growth hormone preparations: Current status and future considerations","volume":"105","author":"Miller","year":"2020","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"279","DOI":"10.4300\/JGME-D-12-00156.1","article-title":"Using effect size-or why the p value is not enough","volume":"4","author":"Sullivan","year":"2012","journal-title":"J. Grad. Med. Educ."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1136\/adc.2004.058222","article-title":"Understanding randomised controlled trials","volume":"90","author":"Akobeng","year":"2005","journal-title":"Arch. Dis. Child."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"a1655","DOI":"10.1136\/bmj.a1655","article-title":"Developing and evaluating complex interventions: The new Medical Research Council guidance","volume":"337","author":"Craig","year":"2008","journal-title":"BMJ"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.ypmed.2017.03.008","article-title":"Medication adherence outcomes of 771 intervention trials: Systematic review and meta-analysis","volume":"99","author":"Conn","year":"2017","journal-title":"Prev. Med."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1136\/adc.2009.175125","article-title":"A systematic review of interventions to enhance medication adherence in children and adolescents with chronic illness","volume":"95","author":"Dean","year":"2010","journal-title":"Arch. Dis. Child."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1016\/S0140-6736(04)17277-2","article-title":"Self-management interventions for chronic illness","volume":"364","author":"Newman","year":"2004","journal-title":"Lancet"},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Haynes, R.B., Ackloo, E., Sahota, N., McDonald, H.P., and Yao, X. (2008). Interventions for enhancing medication adherence. Cochrane Database Syst. Rev., CD000011.","DOI":"10.1002\/14651858.CD000011.pub3"}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/14\/11\/2373\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:10:24Z","timestamp":1760145024000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/14\/11\/2373"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,4]]},"references-count":70,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2022,11]]}},"alternative-id":["pharmaceutics14112373"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics14112373","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,4]]}}}